With $8M seed round, Waltham biotech puts new twist on ‘exon-skipping’

Unlike Sarepta Therapeutics, which makes a drug that skips over faulty exons — parts of genes that encode proteins; Skyhawk Therapeutics is developing treatments for diseases that are caused by exon-skipping.

Scroll to Top